SUMMARY Tissue kallikrein releases kinins by specific proteolysis, an activity inhibited by kallistatin. In this study, kallikrein and kallistatin were localized to endothelial and smooth muscle cells of large, medium, and small normal blood vessels by immunohistochemical techniques. Immunostaining for both proteins was strong in the endothelium of all sizes of blood vessels and was more intense in medial smooth muscle cells of small and mediumsized blood vessels than in elastic arteries. The sites of synthesis by endothelial and smooth muscle cells were demonstrated in normal blood vessels of all sizes by in situ hybridization histochemistry. Kallikrein and kallistatin levels were measured by immunoassays in homogenates of human aorta, vena cava, and iliac artery and vein. Tissue kallikrein and kallistatin transcripts were identified in human blood vessels by RT-PCR followed by Southern blot analysis with specific oligonucleotide probes. The results demonstrated the expression and co-localization of tissue kallikrein and kallistatin in human vessels and suggest a potential role of kallistatin in regulating tissue kallikrein in blood vessels. 
Tissue kallikrein is a serine proteinase that cleaves kininogen to release the kinin peptides bradykinin and lys-bradykinin. Kinins are locally active hormones that participate in the regulation of local blood flow, decrease peripheral vascular resistance, and increase vascular permeability (reviewed in Bhoola et al. 1992) . By binding to endothelial bradykinin B 2 receptors, kinins act as potent vasodilators by stimulating the release of prostacyclin, nitric oxide and endotheliumderived hyperpolarizing factor (reviewing in . Bradykinin B 2 receptor gene knockout in mice demonstrated that a normally functioning B 2 receptor is essential for maintaining cardiovascular homeostasis (Madeddu et al. 1997 ). Kinins have also been shown to affect vascular cell growth (Ziche et al. 1993; Dixon and Dennis 1997) . Angiotensin-converting enzyme (ACE), or kininase II, is a kinin degrading enzyme. Evidence indicates that the reduction of blood pressure and the cardiovascular protective effects of ACE inhibition are, at least in part, due to an increase in kinin levels (Wiemer et al. 1994; . Because the kininogen substrate is abundant in plasma and tissues Figueroa et al. 1992) , the expression and availability of tissue kallikrein are the rate-limiting factors in kinin production.
Human kallistatin is a novel member of the serine proteinase inhibitor (serpin) superfamily which was purified, cloned, and characterized in our laboratory (reviewed in Chao and Chao 1995) . Kallistatin rapidly binds to tissue kallikrein and inhibits its enzymatic activity in vitro , and it profoundly affects the clearance rate of kallikrein in vivo (Xiong et al. 1992) . These studies suggest that kallistatin is a potential physiological regulator of tissue kallikrein. This hypothesis has been further supported by co-localization at the cellular level of kallistatin and tissue kallikrein mRNAs in the human kidney, adrenal gland, and eye (Chen et al. 1995; Ma et al. 1996; Wang et al. 1996) . However, kallistatin is a multifunctional protein that has demonstrated vasodilatory effects independent of an interaction with the kallikrein-kinin system (Chao et al. 1997) . Kallistatin caused an in vivo hypotensive response in a dose-dependent manner, vasodilatation in isolated perfused kidney, and also relaxed isolated aortic rings. Specific binding sites were demonstrated with aorta membrane preparations, indicating that kallistatin may have a direct interaction with smooth muscle cell membrane proteins, resulting in relaxation. Somatic delivery of the kallistatin gene to spontaneously hypertensive rats (SHR) resulted in a significant delay in the elevation of blood pressure for 4 weeks (Chen et al. 1997a) . Our localizations of kallikrein and kallistatin in blood vessels provide a further insight into their potential roles in vascular homeostasis.
Materials and Methods

Tissue Samples for Immunohistochemistry and In Situ Hybridization
Four-m sections were cut from formalin-fixed, paraffinembedded archival surgical specimens. Vessels were examined from a number of anatomic sites, including the pancreas, small intestine, salivary gland, kidney, adrenal glands, aorta, splenic and renal artery and vein, iliac artery, spleen, lymph node, lung, and loose connective tissue, obtained during surgery for metastatic disease, trauma, or reconstruction.
Antibodies for Immunohistochemistry
Details of the isolation and characterization of the monoclonal antibody (MAb) G 4 C 10 , specific for human kallistatin, has been published previously . By Western blot analysis, G 4 C 10 was unreactive towards other serum proteins and other serpins including ␣ 1 -anti-trypsin, ␣ 1 -antichymotrypsin, and rat kallikrein binding protein. The specificity of the rabbit antiserum against human tissue kallikrein has been previously published (Proud and Vio 1993) . To identify endothelial and smooth muscle cells in vessels evaluated for tissue kallikrein and kallistatin, commercially available MAbs to von Willebrand factor and ␣-smooth muscle actin (Dako; Carpinteria, CA), respectively, were used.
Immunohistochemistry
Immunohistochemistry was performed using the TechMate 500 robotic workstation (Ventana; Tucson, AZ) for automated histochemistry. The Steam Heat Induced Epitope Retrieval and MIP (a standard immunoperoxidase procedure using avidin-biotin-peroxidase complex) protocols and ChemMate reagents were used as directed by the manufacturer (Ventana). Color development was performed with diaminobenzidine tetrahydrochloride provided with the ChemMate reagents. For kallistatin immunohistochemistry, MAb G 4 C 10 was used at dilutions of 1:400-1:800. Equally diluted mouse control ascites fluid was used as negative control. Rabbit anti-human tissue kallikrein antiserum was used at dilutions of 1:1200 and 1:2000 to detect kallikrein, and equal dilutions of normal rabbit serum served as negative controls. In control experiments, preabsorption of tissue kallikrein antiserum with purified human tissue kallikrein eliminated immunoreactivity.
In Situ Hybridization Histochemistry
In situ hybridizations specific for kallistatin and tissue kallikrein were performed as previously reported (Chen et al. 1995; Ma et al. 1996; Wang et al. 1996) . A 186-bp human tissue kallikrein cDNA fragment and a 153-bp human kallistatin cDNA fragment were used to generate digoxygenin-UTP-labeled anti-sense and sense riboprobes. Anti-sense riboprobes specific for either tissue kallikrein or kallistatin transcript were used to identify the respective mRNA. Control sections were incubated with a labeled sense riboprobe. Additional controls were pretreated with RNase A before incubation with an anti-sense riboprobe. Liver sections were used as a positive tissue control for kallistatin in situ hybridization. Pancreas sections served as positive control for tissue kallikrein.
Collection of Vessels for ELISA and RT-PCR
Blood vessels removed at autopsy 6-12 hr after death were obtained from the Pathology Department of the Medical University of South Carolina. Total RNA was extracted with Trizol reagent according to the manufacturer's directions (Life Technologies; Rockville, MD). Blood vessels for ELISA were rinsed, minced, and homogenized in PBS, pH 7.4, at 4C. Homogenates were initially centrifuged at 600 ϫ g for 20 min. Supernatants were incubated for 30 min at 4C in 0.5% sodium deoxycholate and centrifuged at 10,000 ϫ g for 30 min, and the pellets discarded. Protein concentration was determined by the Lowry method (Lowry et al. 1951) with bovine serum albumin as the standard.
Tissue Kallikrein and Kallistatin Immunoassays
ELISAs were performed using specific polyclonal antibodies, as previously described, against either tissue kallikrein (Chen et al. 1995) or human kallistatin .
RT-PCR/Southern Blot Analysis for Human Tissue Kallikrein and Kallistatin mRNAs
Reverse transcription (RT) was performed with Moloney murine leukemia virus reverse transcriptase (Life Technologies), 2 g of total RNA, and 100 nmol random hexamers (Life Technologies) according to the manufacturer's protocol. Polymerase chain reaction (PCR) was performed on 1 l of the first-strand cDNA in a 50-l reaction mixture using primers that were designed from unique sequences of human tissue kallikrein (5 Ј primer, AACACAGCCCA-GTTTGT; 3 Ј primer, CTTCAC-ATAAGACAGCAC), human kallistatin (5 Ј primer, CTATGGTTTCGTGGGTC; 3 Ј primer, GGCA-CAATCCAGCTTATC), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (5 Ј primer, ATCCCATCACCATCT-TCCAG; 3 Ј primer, CCTGCTTCACCA-CCTTCTTG). All sets of primers were designed to cross intron-exon boundaries. For tissue kallikrein and kallistatin amplifications of 30 PCR cycles (94C, 1 min; 55C, 1 min; 72C, 1 min) were performed in a thermal cycler, whereas for GAPDH 25 cycles (94C, 1 min; 60C, 1 min; 72C, 1 min) were performed. The PCR product was subjected to Southern blot analysis with a nested oligonucleotide probe specific to the respective gene (tissue kallikrein, GACCTCAAATCCCTGCC; kallistatin, CTCTGGAGTCAGAACCTC; GAPDH, GACCACAGT-CCATGCCAT). Hybridization was carried out as previously described .
Results
Cellular Localization and Expression of Tissue Kallikrein and Kallistatin in Normal Vessels
At low power, the immunohistochemical reactivity for both tissue kallikrein ( Figure 1A ) and kallistatin (Figure 1D ) was more intense in the endothelium and the vasa vasorum than in the media. Overall, the tunica media was more intensely stained for kallistatin than for tissue kallikrein. At higher power, distinct cytoplasmic reactivity was discernible in aortic vascular smooth muscle cells and endothelial cells, and there were increased numbers of medial smooth muscle cells positive for kallistatin ( Figure 1E ) compared to kallikrein ( Figure 1B) . Immunohistochemistry was done with antivon Willebrand factor antibody to identify endothelial cells ( Figure 1C ). The identity of vascular smooth muscle cells was ascertained by immunostaining for ␣-smooth muscle actin ( Figure 1F ). No reactivity was observed when normal rabbit serum was used as a negative control for the rabbit antiserum specific for human tissue kallikrein (not shown) or when anti-kallikrein antiserum was preabsorbed with purified kallikrein (not shown). In addition, reactivity was absent when mouse ascites fluid was used as negative control for the MAb specific for human kallistatin (not shown). Figure 2 illustrates the similar immunohistochemical reactivity for tissue kallikrein (top row) and kallistatin (middle row) that was typical in normal mediumsized (muscular) and small vessels. In comparison to the aorta (Figure 1) , smooth muscle cells in the tunica media of medium-sized vessels and arterioles were more reactive for both proteins. The higher magnification for medium vessels showed nuclei of smooth muscle cells that were often outlined by the intense cytoplasmic staining for both tissue kallikrein (Figures 2A  and 2B ) and kallistatin ( Figures 2D and 2E) . As in the aorta, there was strong cytoplasmic reactivity for tissue kallikrein and kallistatin in endothelial cells of medium and small arteries and veins. Reactivity was absent when normal rabbit serum was used as a negative control ( Figures 2G-2I) for the rabbit antiserum specific for human tissue kallikrein or when anti-kallikrein antibody was preabsorbed with purified kallikrein (not shown). A similar absence of reactivity was seen for control mouse ascites fluid (not shown), used as negative control for the MAb specific for human kallistatin. Figure 3 shows the in situ localization of tissue kallikrein and kallistatin mRNA revealed by using specific digoxygenin-labeled anti-sense riboprobes. Reactivity indicated that both tissue kallikrein (Figures 3A and 3B) and kallistatin ( Figures 3C and 3D ) mRNAs are synthesized by endothelial and smooth muscle cells in the aorta (Figures 3A and 3C ) and small vessels ( Figures 3B and 3D ). Medium vessels (not shown) dis- played positive staining in endothelial and smooth muscle cells similar to the staining seen in aorta and small muscular artery (SMA) in this figure. Reactivity was absent when a sense riboprobe was used for hybridization for tissue kallikrein ( Figures 3E and 3F) or kallistatin (not shown). In addition, no staining was seen when sections were treated with RNase A before hybridization with the respective anti-sense probes (not shown). These results demonstrate the specificity of labeled anti-sense probes for kallistatin or kallikrein transcripts.
Immunoreactive Tissue Kallikrein and Kallistatin Levels in Human Blood Vessels Table 1 shows the levels of immunoreactive human tissue kallikrein and kallistatin in aorta, vena cava, and iliac (muscular) artery and vein measured by ELISA. Human tissue kallikrein levels are greater in the muscular (iliac) vessels than in large, elastic (aorta and vena cava) vessels. In all vessels examined, kallistatin is present in excess of tissue kallikrein. Figure  4 shows a typical curve for the tissue kallikrein standard and curves for immunoreactive kallikrein in serially diluted homogenates of aorta, vena cava, and iliac artery or vein. Dose-dependent curves of sample homogenates are parallel with the standard curve, indicating their immunological identity. Figure 5 shows curves for the kallistatin standard and for immunoreactive kallistatin in the aorta, vena cava, and iliac artery and vein. Lines for the serial dilutions of these samples are also parallel to the standard displacement curve, indicating immunological identity to purified kallistatin used as standard. Figure 6 shows the identification of tissue kallikrein and kallistatin mRNAs in human vessels (aorta, vena Figure 2 Immunohistochemical localization of tissue kallikrein and kallistatin in normal medium-sized (muscular) and small vessels. Endothelial and smooth muscle cells of medium (first two columns) and small (third column) show strong cytoplasmic reactivity for both tissue kallikrein (top row) and kallistatin (middle row). C and F show adjacent sections that contain a small muscular artery (SMA), arteriole (Ar), and venule (Ve). G, H, and I show the absence of reactivity when normal rabbit serum is used as negative control. Sections are not counterstained. Bars: A, B, D cava, iliac artery and vein) as determined by specific RT-PCR amplification and verified by Southern blot analysis. The band migrations were consistent with the expected product sizes and were the same as amplified tissue kallikrein or kallistatin cDNA controls (not shown), indicating that the PCR products were not amplified from genomic DNA. Integrity of the RNAs used in the RT-PCR reactions was evaluated by RT-PCR/Southern analysis for glyceraldehyde-3-phosphate dehydrogenase, a constitutively expressed gene. These results suggest that tissue kallikrein and kallistatin are synthesized locally in vessels and support the results of our in situ hybridization.
Identification of Tissue Kallikrein and Kallistatin Transcripts in Human Vessels by RT-PCR/Southern Blot Analysis
Discussion
This study is the first to demonstrate both the immunohistochemical localization and the in situ synthesis of tissue kallikrein and kallistatin in endothelial and vascular smooth muscle cells of human large, medium and small blood vessels. Our immunohistochemical localization of tissue kallikrein in human vessels is con- Figure 3 In situ hybridization histochemical localization of tissue kallikrein and kallistatin in normal vessels. Positive reactivity is seen in endothelial (black arrows) and smooth muscle cells when anti-sense probes specific for tissue kallikrein (top row) or kallistatin (middle row) were used for hybridization. E and F show the absence of reactivity when tissue kallikrein sense riboprobe was used as a negative control. Abbreviations as in Figure 2 . Bars: A, C, E ϭ 25 ; B, D, F ϭ 50 m.
sistent with a recent localization by Raidoo and coworkers (1997) , except that they did not detect kallikrein in medial smooth muscle cells of large elastic vessels. The discrepancy may be attributed to the fact that their samples were obtained from autopsy and may have undergone some autolysis, rendering medial kallikrein undetectable. Tissue kallikrein and kallistatin are expressed in cultured endothelial cells (Wiemer et al. 1994; Chao et al. 1996) , and kininogenase, kininogen, and kininases have been detected in cultured rat vascular smooth muscle cells (Oza et al. 1990 ). In rat vessels, the presence of a tissue kallikrein-like proteinase and the synthesis of tissue kallikrein mRNA have been previously shown (Nolly et al. 1985; Saed et al. 1990 ). Collectively, these data support the notion that a local kallikrein-kinin system is an integral component of vessels that may participate in the regulation of vascular homeostasis.
The observation that tissue kallikrein appears more pronounced in human medium and small vessels is consistent with previous results revealing a similar pattern for the kininogen substrate , tissue kallikrein activity (Madeddu et al. 1993; Nolly et al. 1992) , and bradykinin receptors (Raidoo et al. 1997) . Physiological studies indicate the importance of the kallikrein-kinin system in regulating the vascular tone in medium and small vessels to control blood flow to tissues. For example, in humans the endothelium-mediated vasodilatation of the radial and coronary arteries (both are muscular arteries) induced by increasing blood flow was found to be kinin-dependent (Cockcroft et al. 1994; Groves et al. 1995; . Pathological conditions such as arterio- Figure 4 ELISA of human tissue kallikrein. The standard curve of purified human tissue kallikrein ranges from 0.2 to 6.4 ng/ml. Homogenates of human aorta, vena cava, and iliac artery and vein were serially diluted and the results graphed to assess parallelism to the standard curve. sclerosis induce progressive impairment of endotheliumdependent vasodilatation in these vessels and promote generation of vasoconstrictors. ACE inhibition may help restore an important kinin-mediated function to the endothelium because it has been found to induce a 10-fold potentiation of the action of kinins in the coronary circulation (Hecker et al. 1994; Bossaller et al. 1992) . Kinins also contribute significantly to the inflammatory response by mediating vasodilatation and increasing vascular permeability . Tissue kallikrein has been localized to neutrophils (Figueroa et al. 1989) and may contribute to the extravasation of neutrophils from vessels and into tissues, a process that further contributes to increased permeability and edema. It is possible that the presence of kallistatin in vessels may provide anti-inflammatory protection. Overexpression in mice of rat kallikrein-binding protein significantly increased survival during endotoxic shock (Chen et al. 1997b ). In humans, plasma kallistatin, normally about 21 mg/liter, declined to almost a third of this level during sepsis, which implies a consumption during systemic inflammatory reactions .
Kallistatin is a heparin-binding serpin, and its interaction with tissue kallikrein is markedly attenuated by heparin binding ). Many heparin binding serpins also interact with and are modulated by heparan sulfates and other glycosaminoglycans found in the vascular extracellular matrix and on endothelial and smooth muscle cell surfaces (Carlson et al. 1995; Shirk et al. 1996) . The vascular functions of kallistatin may be similarly modulated. The co-localization of kallikrein and kallistatin in blood vessels strengthens the likelihood that they may co-exist as enzyme and inhibitor there and in other tissues. The interactions of kallikrein and kallistatin with other constituents of blood vessels and the role of the kallikreinkinin system in cardiovascular pathophysiology are subjects of ongoing investigations.
